+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Sarcoma

  • ID: 4462140
  • Report
  • October 2020
  • Region: Global
  • 55 Pages
  • Datamonitor Healthcare
This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2019, there were approximately 430,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 503,700 incident cases by 2028.

Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (85%), while a smaller proportion were osteosarcomas and malignant bone tumors (15%).

The approved drugs in the sarcoma space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.

The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, topical, and subcutaneous formulations.

High-impact upcoming events for drugs in the sarcoma space comprise topline Phase II trial results for ADP-A2M4 and topline Phase Ib/II trial results for ABI-009.

The overall likelihood of approval of a Phase I sarcoma asset is 10%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.5 years from Phase I to approval in the sarcoma space as well as in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major European markets, while Israel has the top spot in Asia.

Clinical trial activity in the sarcoma space is dominated by completed trials. Merck & Co and Novartis have the highest number of completed clinical trials for sarcoma, with 21 trials each.

Merck & Co leads industry sponsors with the highest overall number of clinical trials for sarcoma, followed by Bristol Myers Squibb and Novartis.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Targeted therapies
EPIDEMIOLOGY
  • Epidemiological disease definition
MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Keytruda for Sarcoma (September 20, 2020)
  • ADP-A2M4 for Sarcoma (May 29, 2020)
  • Tazverik for Sarcoma (December 18, 2019)
  • Tazverik for Sarcoma (December 16, 2019)
  • Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Tazverik for Sarcoma (June 3, 2019)
  • Lartruvo for Sarcoma (June 2, 2019)
  • Hensify for Sarcoma (April 4, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Tazverik Accelerated Approval: Disease Rarity And Unmet Need Won Out Over Efficacy Concerns
  • Takara Bio’s Mipetresgene Autoleucel Receives Orphan Regenerative Medicine Designation For Synovial Sarcoma
  • Tazverik Nabs Accelerated Approval Despite FDA Concerns About Confirmatory Trial
  • Adaptimmune SPEARs An RMAT For Synovial Sarcoma
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • PharmaMar Licenses Yondelis To TTY In Three Asian Markets
  • Deals Shaping The Medical Industry, February 2020
  • STA Acquires Australian, Asian Rights To Yondelis
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

List of Figures
  • Figure 1: Trends in incident cases of sarcoma, 2019-28
  • Figure 2: Incident cases of sarcoma, by age, 2019
  • Figure 3: Incident cases of sarcoma, by tumor type, 2019
  • Figure 4: Overview of pipeline drugs for sarcoma in the US
  • Figure 5: Pipeline drugs for sarcoma, by company
  • Figure 6: Pipeline drugs for sarcoma, by drug type
  • Figure 7: Pipeline drugs for sarcoma, by classification
  • Figure 8: Keytruda for Sarcoma (September 20, 2020): Phase II - AcSé
  • Figure 9: Bempegaldesleukin for Sarcoma (June 3, 2019): Phase II - w/Nivolumab
  • Figure 10: Tazverik for Sarcoma (June 3, 2019): Phase II - INI1-Negative Tumors
  • Figure 11: Lartruvo for Sarcoma (June 2, 2019): Phase III - ANNOUNCE (w/Doxorubicin)
  • Figure 12: Key upcoming events in sarcoma
  • Figure 13: Probability of success in the sarcoma pipeline
  • Figure 14: Clinical trials in sarcoma
  • Figure 15: Top 10 drugs for clinical trials in sarcoma
  • Figure 16: Top 10 companies for clinical trials in sarcoma
  • Figure 17: Trial locations in sarcoma
  • Figure 18: Sarcoma trials status
  • Figure 19: Sarcoma trials sponsors, by phase
List of Tables
  • Table 1: Incident cases of sarcoma, 2019-28
  • Table 2: Marketed drugs for sarcoma
  • Table 3: Pipeline drugs for sarcoma in the US
  • Table 4: Keytruda for Sarcoma (September 20, 2020)
  • Table 5: ADP-A2M4 for Sarcoma (May 29, 2020)
  • Table 6: Tazverik for Sarcoma (December 18, 2019)
  • Table 7: Tazverik for Sarcoma (December 16, 2019)
  • Table 8: Bempegaldesleukin for Sarcoma (June 3, 2019)
  • Table 9: Tazverik for Sarcoma (June 3, 2019)
  • Table 10: Lartruvo for Sarcoma (June 2, 2019)
  • Table 11: Hensify for Sarcoma (April 4, 2019)
  • Table 12: Historical global sales, by drug ($m), 2015-19
  • Table 13: Forecasted global sales, by drug ($m), 2020-24
Note: Product cover images may vary from those shown
Adroll
adroll